This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MADIT-II was a completed phase 4, randomized, parallel-group trial evaluating remote follow-up of patients receiving an implantable cardioverter defibrillator for prophylactic therapy. The registry identifies ventricular fibrillation and ventricular tachycardia as the trial conditions and lists number of follow-up visits at 27 months as the primary endpoint.
| Feature | MADIT-II |
|---|---|
| Acronym | MADIT-II |
| Trial title | Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy |
| Phase | Phase 4 |
| Status | Completed |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Health services research |
| Enrollment | 155 |
| Number of arms | 2 |
| Intervention | Implantable Cardioverter Defibrillator (device) |
| Conditions | Ventricular Fibrillation; Ventricular Tachycardia |
| Lead sponsor | Biotronik SE & Co. KG |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT00401466 |
2. Clinical Question
The registry describes MADIT-II as a study of remote follow-up among patients receiving an implantable cardioverter defibrillator for prophylactic therapy. Its registered primary endpoint is the number of follow-up visits at 27 months.
Population
Patients receiving an implantable cardioverter defibrillator for prophylactic therapy in the setting of ventricular fibrillation or ventricular tachycardia.
Intervention
Implantable Cardioverter Defibrillator (device).
Comparator
The registry identifies a randomized two-arm design but does not report the comparator description in the record summarized here.
Primary question
How does the randomized study design relate to the number of follow-up visits measured at 27 months?
3. Trial Design
The combination of randomization and a parallel design establishes the basic structure for a between-group comparison. Because the registry does not provide arm-specific enrollment, the allocation ratio cannot be reconstructed from the record. Likewise, the record summarized here does not identify the exact operational distinction between the two arms.
4. Trial Timeline
Trial start
The registry lists the study start date as 2004-01.
Study period
The study was conducted under a randomized, parallel-group design with 155 enrolled participants.
Primary completion
The registry lists the primary completion date as 2008-07.
Registry status
The current registry record identifies the study as completed.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Number of follow-up visits | Number of follow-up visits | 27 months |
The endpoint is a count of follow-up visits, rather than a conventional clinical time-to-event endpoint such as death, disease progression, or recurrence. That distinction determines the appropriate statistical framework.
The statistical outcome is a nonnegative count. Unlike a continuous measurement, a visit count is discrete and may have a skewed distribution or unequal variability across treatment groups.
6. Planned Analysis
No formal statistical analyses are posted to ClinicalTrials.gov. The registry does, however, identify the primary outcome that was to be measured: the number of follow-up visits at 27 months.
How a count endpoint is typically analysed
A count outcome can be summarized by treatment group using measures such as the mean, median, standard deviation, interquartile range, and observed range when appropriate. A simple comparison of group means may be reasonable when the distribution is sufficiently well behaved, but count data often require methods that account explicitly for their discrete nature.
For a randomized two-arm study, a regression model for count data can provide an adjusted comparison while preserving the randomized treatment contrast. A Poisson regression model is a standard starting point when the conditional mean and variance are reasonably compatible with the Poisson assumption.
Here, Y is the number of follow-up visits and T indicates randomized treatment group. Exponentiating β1 produces a rate ratio comparing the expected visit counts between groups under the fitted model.
Overdispersion
A central diagnostic issue is whether the variability in the visit count is larger than expected under a Poisson model. If the variance substantially exceeds the mean, negative binomial regression or a Poisson model with robust variance can be considered. The appropriate choice depends on the observed distribution and the prespecified statistical analysis plan.
Exposure and follow-up time
The registry defines the endpoint at 27 months. If every participant contributes the same observation period, the analysis can focus directly on the count of visits. If participants have materially different observation times because of withdrawal, loss to follow-up, or other mechanisms, an analysis based on a visit rate with an appropriate exposure-time offset may be more informative.
Zero counts and distributional shape
Count outcomes can contain many small values and may include zero. A frequency distribution or histogram should therefore be inspected before selecting a model. If there are substantially more zero counts than expected under the selected count model, specialized approaches may be required.
7. Statistical Methodology
Randomization and treatment comparison
Randomization is the key design feature supporting a causal comparison between the two study arms. In principle, random assignment balances both measured and unmeasured prognostic factors in expectation. It does not guarantee identical baseline characteristics in a finite sample, but it establishes the treatment assignment mechanism needed for a valid primary comparison.
For a primary count endpoint, the analysis should preserve that randomized comparison. The principal parameter could be expressed as a difference in mean visit counts, a ratio of expected counts, or a rate ratio, depending on the prespecified model.
Descriptive analysis of a count
The first analytical step should be descriptive. The distribution of follow-up visits should be examined separately by randomized group. The mean describes the average number of visits, while the median describes the central observation and is less sensitive to extreme values. The standard deviation describes dispersion around the mean, whereas the interquartile range describes the middle half of the distribution.
Mean difference
A difference in means answers how many more or fewer visits, on average, occurred in one randomized group than the other.
Rate ratio
A rate ratio compares expected visit rates between groups when observation time or exposure differs.
Median difference
A median comparison focuses on the central participant rather than the average number of visits.
Distributional assessment
Because visits are counts, the shape of the outcome distribution is itself an important component of model selection.
Poisson regression
Poisson regression models the logarithm of the expected count as a function of treatment and, when appropriate, additional prespecified covariates. The exponentiated treatment coefficient is interpreted as a multiplicative comparison of expected counts.
An estimated ratio of 1 indicates equal expected counts under the model. A ratio below 1 indicates a lower expected count in the treatment-coded group, while a ratio above 1 indicates a higher expected count.
Negative binomial regression
Negative binomial regression extends the Poisson framework by allowing greater variability than the Poisson distribution permits. This is especially relevant when participants differ substantially in their propensity to have follow-up visits, producing overdispersion.
Robust inference
When the mean structure of a Poisson model is useful but the variance assumption is questionable, robust standard errors can provide inference that is less dependent on the strict Poisson variance relationship. The choice should be prespecified or justified by the observed data and study objectives.
8. Statistical Methods Explained
Why does randomization matter for a follow-up-visit endpoint?
Randomization determines how patients enter the two comparison groups. For a health-services endpoint such as follow-up visits, this matters because visit frequency can be influenced by many patient and system characteristics. Randomization provides the foundation for attributing a between-group difference to the randomized study strategy rather than to deliberate allocation based on those characteristics.
Why is the number of visits a count endpoint?
The outcome can take discrete nonnegative values: a participant can have a certain number of visits, rather than a measurement that varies continuously over an unrestricted numerical scale. Count outcomes therefore have statistical properties that differ from continuous endpoints such as blood pressure or laboratory measurements.
Why might a Poisson model be considered?
Poisson regression was developed for count outcomes and directly models the expected number of events or occurrences. It also produces a multiplicative treatment comparison that can be expressed as a rate ratio or count ratio.
What is overdispersion?
Overdispersion occurs when the observed variability in a count outcome is greater than the Poisson model assumes. Ignoring substantial overdispersion can make standard errors too small and confidence intervals too narrow. Negative binomial models and robust variance methods are common ways to address this problem.
Why might the visit rate be more useful than the raw count?
If participants contribute different amounts of observation time, simply comparing counts can confound the outcome with the amount of time available to accumulate visits. A rate-based model accounts for exposure time, often through an offset, so that the comparison reflects visits per unit of observation rather than only the accumulated count.
What does a confidence interval add?
A confidence interval quantifies statistical uncertainty around an estimated treatment contrast. It does not describe the range of outcomes experienced by individual participants, and it does not measure the probability that a particular hypothesis is true.
9. Analysis Population and Missing Follow-up
The registry identifies 155 enrolled participants and a randomized design, but the record summarized here does not specify separate analysis-population definitions or the number of participants contributing endpoint data at 27 months.
For a randomized primary analysis, the preferred population is generally defined according to the prespecified randomized analysis set. For a follow-up-visit count, however, missing observation time creates an additional issue: a participant who is observed for only part of the planned period has fewer opportunities to accumulate visits than someone observed for the complete period.
Incomplete follow-up
The amount of observation time should be distinguished from the number of visits actually observed.
Missing endpoint data
The mechanism and extent of missing follow-up information affect the interpretation of any group comparison.
Exposure-time adjustment
If observation time differs materially, a rate model can account for unequal opportunities to accumulate visits.
Sensitivity analysis
Alternative assumptions about incomplete follow-up can be examined when missingness could materially influence the result.
The registry does not report a missing-data or imputation strategy for the primary endpoint. For a count of visits, imputing an unobserved number of visits is not automatically preferable to modelling the observation process or using available follow-up time appropriately.
10. Multiplicity and Secondary Analyses
The registry record summarized here identifies one registered primary endpoint: number of follow-up visits at 27 months. It does not report additional registered primary endpoints, secondary endpoint analyses, multiplicity procedures, or an endpoint hierarchy.
Multiplicity becomes important when several hypotheses are tested. If multiple endpoints, time points, treatment contrasts, or subgroup comparisons are formally tested, the probability of at least one false-positive finding can increase unless the testing strategy accounts for the multiplicity.
| Statistical feature | Registry record |
|---|---|
| Registered primary endpoint | Number of follow-up visits |
| Primary time frame | 27 months |
| Additional primary endpoints | Not reported |
| Multiplicity procedure | Not reported |
| Endpoint hierarchy | Not reported |
11. Interim Analysis
The registry record does not report an interim statistical analysis, interim efficacy boundary, alpha-spending procedure, or group-sequential design.
Interim analysis is particularly important in trials where accumulating data are examined before the planned final analysis. Repeated unadjusted significance testing can increase the type I error rate. A prespecified group-sequential framework can instead allocate the overall error budget across interim and final analyses.
Formal interim monitoring requires a prespecified statistical framework if efficacy conclusions are to retain their intended error-control properties.
12. Non-Inferiority, Crossover, and Bayesian Methods
The registry record does not report a non-inferiority margin, crossover design, Bayesian analysis, or Bayesian decision rule.
| Design topic | Registry record |
|---|---|
| Non-inferiority margin | Not reported |
| Crossover | Not reported |
| Factorial design | Not reported |
| Bayesian methods | Not reported |
| Interim analysis | Not reported |
These distinctions matter because each design feature changes the statistical interpretation. A non-inferiority trial requires comparison with a prespecified margin; crossover trials require within-person period and treatment considerations; factorial trials estimate effects across more than one intervention factor; and Bayesian analyses use posterior distributions rather than relying exclusively on frequentist confidence intervals and p-values.
13. Safety and Clinical Outcomes
The registry record identifies ventricular fibrillation and ventricular tachycardia as conditions and an implantable cardioverter defibrillator as the intervention. It does not provide arm-specific serious adverse-event counts, adverse-event rates, mortality outcomes, or other clinical outcome estimates in the statistical information summarized here.
Safety analysis should be kept conceptually separate from the primary health-services endpoint. A count of follow-up visits describes healthcare utilization or follow-up activity; it does not by itself establish the safety or clinical efficacy of the device.
14. Why the Primary Endpoint Determines the Statistics
One of the most important statistical lessons from MADIT-II is that the endpoint determines the appropriate analytical framework. A trial involving an implantable medical device might suggest survival analysis to many readers, but the registered primary endpoint here is not survival time. It is a number of follow-up visits at 27 months.
| Endpoint structure | Typical statistical framework |
|---|---|
| Continuous measurement | Mean difference, linear regression, ANCOVA, or related continuous-outcome methods |
| Binary outcome | Risk difference, risk ratio, odds ratio, logistic regression |
| Time-to-event outcome | Kaplan-Meier estimation, log-rank test, Cox regression |
| Count outcome | Poisson regression, negative binomial regression, or other count models |
| Repeated count outcome | Longitudinal count models or other repeated-measures approaches |
The same randomized trial can contain several endpoint types, each requiring a different model. Statistical analysis should therefore begin by identifying exactly what is being measured, when it is measured, and how the outcome is distributed.
15. What a Treatment Effect Would Mean for a Visit Count
Suppose the primary comparison produced a rate ratio for the number of follow-up visits. The interpretation would be multiplicative rather than a statement that an identical number of visits was added or removed for every participant.
A rate ratio below 1 would indicate a lower expected follow-up-visit count or rate in the treatment-coded group under the fitted model. A rate ratio above 1 would indicate a higher expected count or rate.
The ratio would not mean that every individual participant experienced the same proportional change in visits. It would also not establish that the difference was clinically beneficial or harmful without understanding why visit frequency differed.
A confidence interval around a rate ratio describes uncertainty in the estimated group contrast. A narrow interval indicates greater statistical precision than a wide interval, all else equal. The interval does not describe the range of individual patients' visit counts.
A p-value evaluates the compatibility of the observed data with a specified null hypothesis under the statistical model. It does not measure the size of the treatment effect, the clinical importance of the difference, or the probability that one treatment strategy is superior.
16. Randomization Does Not Solve Every Statistical Problem
Randomization is powerful, but it does not eliminate all analytical challenges. In a health-services endpoint such as follow-up visits, the amount of follow-up, the distribution of counts, and the mechanisms producing additional visits can all influence the observed outcome.
Randomization
Protects the treatment comparison from intentional allocation based on known patient characteristics.
Outcome distribution
Still determines whether a simple comparison or a count regression model is appropriate.
Observation time
Can affect the number of opportunities a participant has to accumulate visits.
Interpretation
A statistically detectable difference in visits does not automatically establish a clinical benefit.
17. Important Limitations and Interpretation Issues
- No posted statistical analyses: the ClinicalTrials.gov record does not report formal statistical analyses for the registered primary endpoint.
- Limited endpoint detail: the registered primary endpoint is identified as number of follow-up visits at 27 months, but the record summarized here does not provide the arm-specific visit counts or a detailed statistical analysis plan.
- Comparator description: the registry identifies a randomized two-arm design, but the comparator description is not reported in the record summarized here.
- Analysis population: the record does not provide a separate primary analysis-population definition or the number of participants contributing endpoint data at 27 months.
- Missing follow-up: the registry does not report a missing-data or imputation strategy for the primary endpoint.
- Count distribution: the appropriate model depends on the observed distribution of follow-up visits, including whether there is substantial overdispersion or an excess of zero counts.
- Observation time: if participants have unequal follow-up, raw visit counts may not adequately represent visit frequency without accounting for exposure time.
- Clinical interpretation: the number of follow-up visits is a health-services endpoint and should not be treated as a direct measure of clinical efficacy or safety.
- Unreported design features: the registry record does not report subgroup analyses, interim analyses, multiplicity procedures, non-inferiority margins, crossover, factorial structure, or Bayesian methods.
18. Why This Trial Matters Statistically
MADIT-II is useful as a statistical teaching case because it illustrates an important point that can be obscured by the medical context of a device trial: The statistical method should follow the endpoint actually registered for analysis.
| Concept | How it appears in MADIT-II |
|---|---|
| Randomization | Patients were randomized to 2 arms. |
| Parallel design | The registry identifies a parallel-group design. |
| Unmasked design | Masking is listed as none. |
| Health-services research | The registry identifies health services research as the primary purpose. |
| Count endpoint | The primary endpoint is number of follow-up visits. |
| Fixed assessment time | The primary endpoint is assessed at 27 months. |
| Count regression | Poisson or negative binomial methods are natural candidate frameworks for a visit-count endpoint. |
| Overdispersion | The variance of the observed count distribution should be assessed before relying on a Poisson variance assumption. |
| Exposure time | Unequal follow-up can make rate-based analysis more appropriate than a simple count comparison. |
| Interpretation | A healthcare-utilization endpoint should not automatically be interpreted as a clinical outcome. |
19. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The primary endpoint is a count measured at 27 months. The appropriate analysis should compare the randomized groups using a method that accounts for the discrete distribution of visit counts and, if necessary, unequal observation time or overdispersion.
Clinical interpretation
The meaning of a difference in follow-up visits depends on why visits occurred and what the follow-up strategy was intended to accomplish. Visit frequency alone does not establish a clinical outcome.
20. Statistical Concepts in This Trial
The MADIT-II registry record provides a compact example of how trial design, endpoint classification, and statistical modelling fit together. The most important analytical sequence is to identify the randomized comparison, define the outcome precisely, inspect its distribution, and then select a model that matches that outcome.
Each step contributes something different. Randomization defines the comparison, endpoint definition determines the data structure, model choice determines the statistical contrast, and uncertainty measures determine how precisely that contrast has been estimated.
21. Sources
- ClinicalTrials.gov: MADIT-II, NCT00401466.
Continue through Clinical Biostats
Explore statistical methods, clinical-trial concepts, and analysis tools for understanding randomized clinical research.
22. Record Summary
MADIT-II is a completed phase 4 randomized, parallel-group study enrolling 155 participants in 2 arms. The registry identifies implantable cardioverter defibrillator therapy, ventricular fibrillation and ventricular tachycardia, and health services research as central elements of the study. Its registered primary endpoint is the number of follow-up visits at 27 months.
From a statistical perspective, that endpoint is fundamentally a count outcome. The central analytical questions therefore concern the distribution of visit counts, whether the variance is compatible with a Poisson model, whether observation time is comparable between participants, and whether a simple count comparison or a regression-based rate comparison is most appropriate. The randomized design provides the framework for the between-group comparison, while the endpoint's structure determines the statistical model.